Clinical Trial Update: A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China [Phase 1]

View source ↗

Summary

Phase 1 study of Vepdegestrant (ARV-471) for ER+/HER2- advanced breast cancer in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vepdegestrant (ARV-471)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED